Stride Arcolab has received approval for Rifampicin for Injection USP, 600mg/vial. The product is licensed to Akorn-Strides, LIC, which is a joint venture that was formed in 2004 by Akorn Inc. and Strides Arcolab Ltd.

Arun Kumar, vice chairman and Group CEO of Strides Arcolab, said, "These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for seven sterile injectable products and plans for commercialization are underway".

Strides have 14 manufacturing plans spread across the Brazil, Mexico, Italy, Poland, Singapore and India. This broad manufacturing network facilities partnering with global organizations ranging from UNICEF and WHO-global drug facility to Europen and American pharmaceutical multinationals.